These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 32480224

  • 1. Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment.
    Chen B, Pan Y, Xu X, Wu F, Zheng X, Chen SY, Zhao YT, Huang Z, Cheng SH, Liu JX, Wang WH, Li YX.
    Biomed Pharmacother; 2020 Aug; 128():110284. PubMed ID: 32480224
    [Abstract] [Full Text] [Related]

  • 2. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
    Wang P, Jiang Z, Liu X, Yu K, Wang C, Li H, Zhong L.
    Cancer Med; 2020 Oct; 9(19):6972-6983. PubMed ID: 32779397
    [Abstract] [Full Text] [Related]

  • 3. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 4. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
    Song Z, Liu T, Chen J, Ge C, Zhao F, Zhu M, Chen T, Cui Y, Tian H, Yao M, Li J, Li H.
    Cancer Lett; 2019 Sep 28; 460():96-107. PubMed ID: 31247273
    [Abstract] [Full Text] [Related]

  • 5. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, Zhang H, Zi X, Zhou W, Huang G.
    Biomed Pharmacother; 2020 Sep 28; 129():110315. PubMed ID: 32554246
    [Abstract] [Full Text] [Related]

  • 6. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y.
    Cell Death Dis; 2021 Jul 09; 12(7):691. PubMed ID: 34244479
    [Abstract] [Full Text] [Related]

  • 7. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 09; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 8. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.
    Gastroenterology; 2016 Dec 09; 151(6):1192-1205. PubMed ID: 27614046
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
    Wu L, Zhou J, Zhou W, Huang XF, Chen Q, Wang W, Zhai L, Li S, Tang Z.
    Pathol Res Pract; 2021 Apr 09; 220():153270. PubMed ID: 33640712
    [Abstract] [Full Text] [Related]

  • 10. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B.
    Aging (Albany NY); 2020 Nov 16; 12(22):22975-23003. PubMed ID: 33203790
    [Abstract] [Full Text] [Related]

  • 11. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Chen Y, Feng F, Gao X, Wang C, Sun H, Zhang C, Zeng Z, Lu Y, An L, Qu J, Wang F, Yang Y.
    Curr Cancer Drug Targets; 2015 Nov 16; 15(3):176-87. PubMed ID: 25714700
    [Abstract] [Full Text] [Related]

  • 12. Resveratrol suppresses liver cancer progression by downregulating AKR1C3: targeting HCC with HSA nanomaterial as a carrier to enhance therapeutic efficacy.
    Wang Y, Su L, Hu Z, Peng S, Li N, Fu H, Wang B, Wu H.
    Apoptosis; 2024 Oct 16; 29(9-10):1429-1453. PubMed ID: 39023830
    [Abstract] [Full Text] [Related]

  • 13. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 14. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
    Ma D, Wang J, Liu L, Chen M, Wang Z.
    BMC Cancer; 2020 Sep 29; 20(1):936. PubMed ID: 32993568
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
    Osawa M, Matsuda Y, Kinoshita Y, Wakai T.
    Anticancer Res; 2021 Feb 29; 41(2):645-660. PubMed ID: 33517269
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
    Wang J, Xia C, Pu M, Dai B, Yang X, Shang R, Yang Z, Zhang R, Tao K, Dou K.
    Oncol Rep; 2018 Oct 29; 40(4):1875-1884. PubMed ID: 30015982
    [Abstract] [Full Text] [Related]

  • 19. Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer.
    Li P, Hu T, Wang H, Tang Y, Ma Y, Wang X, Xu Y, Chen G.
    Mol Med Rep; 2019 Sep 29; 20(3):2493-2499. PubMed ID: 31322213
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.